Eosinophilic Asthma Clinical Trials

43 clinical trials for Eosinophilic Asthma across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma — RECRUITING · PHASE2
• Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment — RECRUITING · PHASE3
• Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA — RECRUITING · PHASE4
• THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECT OF DEPEMOKIMAB ON AIRWAY STRUCTURE AND FUNCTION IN ASTHMA WITH TYPE 2 INFLAMMATION CHARACTERIZED BY AN EOSINOPHILIC PHENOTYPE UTILIZING QUANTITATIVE HIGH-RESOLUTION CT AND BRONCHOSCOPIC AIRWAY SAMPLING IN A SUB-STUDY — RECRUITING · PHASE3
• BRISOTE: A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE-CONTROLLED, PHASE 3B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB 30 MG SC IN EOSINOPHILIC ASTHMA PATIENTS UNCONTROLLED ON MEDIUM-DOSE INHALED CORTICOSTEROID PLUS LONG-ACTING B2-AGONIST — RECRUITING · PHASE3
• A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY ASSESSING EXACERBATION RATE, ADDITIONAL MEASURES OF ASTHMA CONTROL AND SAFETY IN ADULT AND ADOLESCENT SEVERE ASTHMATIC PARTICIPANTS WITH AN EOSINOPHILIC PHENOTYPE TREATED WITH GSK3511294 COMPARED WITH MEPOLIZUMAB OR BENRALIZUMAB — RECRUITING
• EFFICACY OF RESLIZUMAB DOSE ESCALATION IN PATIENTS WITH SEVERE ASTHMA AND PERSISTENT SPUTUM EOSINOPHILIA DESPITE STANDARD DOSE THERAPY. — RECRUITING
• Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils — RECRUITING
• A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON STRUCTURAL AND LUNG FUNCTION CHANGES IN SEVERE EOSINOPHILIC ASTHMATICS (CHINOOK) — RECRUITING · PHASE4
• A MECHANISTIC PILOT OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON AIRWAY FUNCTION AND INFLAMMATION IN PATIENTS WITH SEVERE, POORLY-CONTROLLED EOSINOPHILIC ASTHMA USING INHALED HYPERPOLARIZED 129XE MRI (AERFLO) — RECRUITING
• Fasenra: An Asthma Study — NOT_YET_RECRUITING · PHASE4
• Eosinophils Endotypes in Chronic Airway Inflammatory Diseases — COMPLETED
• BRISOTE: A Multicentre, Randomised, Double-blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist — TERMINATED · PHASE3
• Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma — COMPLETED
• Phase III Long-Term Extension Study With Dexpramipexole — TERMINATED · PHASE3
• A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. — TERMINATED · PHASE3
• A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) — TERMINATED · PHASE3
• A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma — NOT_YET_RECRUITING · PHASE2
• AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma — COMPLETED · PHASE1
• A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma — ACTIVE_NOT_RECRUITING · PHASE3
• A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4) — OTHER · PHASE3
• AN OPEN-LABEL LONG-TERM PHASE III EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DEXPRAMIPEXOLE IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA (EXHALE 5) — COMPLETED · PHASE3
• Eosinophil Subpopulations in Eosinophilic-associated Diseases — NOT_YET_RECRUITING
• Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA (EXHALE-2) — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 24 WEEKS IN PARTICIPANTS WITH EOSINOPHILIC ASTHMA (EXHALE-4) — COMPLETED
• Effect of Mepolizumab on Severe Eosinophilic Asthma — OTHER
• Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma — COMPLETED · PHASE2
• Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma — COMPLETED · PHASE2
• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, TIME-TO-FIRST ASTHMA EXACERBATION PHASE 3 EFFICACY AND SAFETY STUDY OF BENRALIZUMAB IN PAEDIATRIC PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA (DOMINICA) — COMPLETED · PHASE3
• Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma — OTHER
• A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma — COMPLETED · PHASE3
• XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma — COMPLETED · PHASE2
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACODYNAMICS OF TEV 53275 ADMINISTERED SUBCUTANEOUSLY IN ADULT PATIENTS WITH PERSISTENT EOSINOPHILIC ASTHMA — COMPLETED · PHASE2
• Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". — OTHER · PHASE4
• A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil — OTHER · PHASE4
• Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma — COMPLETED
• Intense Airway Eosinophilia in Asthma — COMPLETED
• PONENTE: A MULTICENTER, OPEN-LABEL, PHASE 3B EFFICACY AND SAFETY STUDY OF BENRALIZUMAB 30 MG ADMINISTERED SUBCUTANEOUSLY TO REDUCE ORAL CORTICOSTEROID USE IN ADULT PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ON HIGH DOSE INHALED CORTICOSTEROID PLUS LONG ACTING 2 AGONIST AND CHRONIC ORAL CORTICOSTEROID THERAPY — COMPLETED · PHASE3
• Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma — COMPLETED · PHASE3
• Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma — TERMINATED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma — COMPLETED · PHASE3

Refine this search